ArticleRadiology2022
Chest CT-based Assessment of 1-year Outcomes after Moderate COVID-19 Pneumonia.
Article in Radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 76 citations in OpenAlex.
- Longitudinal Assessment of Chest Computed Tomographic Findings After COVID-19 Infection.Cureus · 2026Article
- Prevalence and outcomes of SARS-CoV-2 infection in ILD: Post-pandemic study in South Italy.Multidisciplinary respiratory medicine · 2026Article
- ICU predictive factors of fibrotic changes following COVID-19 related ARDS: a RECOVIDS substudy.Annals of intensive care · 2025Article
- Impact of oxygenation strategies on outcome in acute exacerbation of interstitial lung disease.ERJ open research · 2025Article
- The post-COVID-19 pulmonary sequelae: manifestations, mechanisms and treatment strategies.Journal of thoracic disease · 2025Review
- Association of Pulmonary Involvement at Baseline with Exercise Intolerance and Worse Physical Functioning 8 Months Following COVID-19 Pneumonia.Journal of clinical medicine · 2025Article
- The RACOON viral pneumonia score for structured reporting of pre-existing, acute, and post-pneumonic findings on chest CT.Frontiers in medicine · 2025Article
- Long-term pulmonary sequelae and convalescent immune reactions in mild to moderate COVID-19 patients during the active treatment era.PloS one · 2025Article
- Assessment of chest CT abnormalities and pulmonary function at 6-month and 1-year after hospital discharge in Chinese patients of COVID-19 pneumonia at the turn of 2022-2023.Frontiers in medicine · 2025Article
- Functional and radiological changes in ICU survivors with COVID-19 at 1-year follow-up from the OUTSTRIP COVID-19 study.Qatar medical journal · 2025Article
- Effects of acute-phase COVID-19-related indicators on pulmonary fibrosis and follow-up evaluation.European journal of medical research · 2024Article
- Long-Term Pulmonary Sequelae and Immunological Markers in Patients Recovering from Severe and Critical COVID-19 Pneumonia: A Comprehensive Follow-Up Study.Medicina (Kaunas, Lithuania) · 2024Observational
- Early pulmonary fibrosis-like changes between delta and pre-delta periods in patients with severe COVID-19 pneumonia on mechanical ventilation.Scientific reports · 2024Article
- The impact of pulmonary embolism on health outcomes of COVID-19 at 3 months after hospitalization.Research and practice in thrombosis and haemostasis · 2024Article
- Lung volume measurement using chest CT in COVID-19 patients: a cohort study in Japan.BMJ open respiratory research · 2024Article
- Impact of COVID-19 on quality of life in survivors with pulmonary sequelae.Scientific reports · 2024Observational
- Short- and Long-Term Chest-CT Findings after Recovery from COVID-19: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2024Review
- Quantitative CT Texture Analysis of COVID-19 Hospitalized Patients during 3-24-Month Follow-Up and Correlation with Functional Parameters.Diagnostics (Basel, Switzerland) · 2024Article
- CT-based Assessment at 6-Month Follow-up of COVID-19 Pneumonia patients in China.Scientific reports · 2024Article
- CT abnormalities 3 and 12 months after hospitalization for COVID-19 and association with disease severity: A prospective cohort study.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-19 pneumonia may lead to pulmonary fibrosis in the long term. Chest CT is useful to evaluate changes in the lung parenchyma over time. PURPOSE: To illustrate the temporal change of lung abnormalities on chest CT scans associated with COVID-19 pneumonia over 1 year. MATERIALS AND
methodsIn this prospective study, patients previously hospitalized due to COVID-19 pneumonia who visited the radiology department of a tertiary care center for imaging follow-up were consecutively enrolled between March 2020 and July 2021. Exclusion criteria were acute respiratory distress syndrome, requirement of intubation and/or mechanical ventilation, pulmonary embolism, and any interstitial lung disease. High-resolution volumetric noncontrast chest CT scans were acquired at 3, 6, and 12 months from the first diagnosis and were compared with baseline CT scans. The imaging features analyzed were ground-glass opacity (GGO), consolidation, pleuroparenchymal band, linear atelectasis, bronchiectasis and/or bronchiolectasis, reticulation, traction bronchiectasis and/or bronchiolectasis, and honeycombing. The prevalence distribution of lung abnormalities was recorded at all time points.
resultsEighty-four participants (56 men; mean age, 61 years ± 11 [SD]) were studied. GGOs and consolidations represented the main baseline lung abnormalities, accounting for a median severity score of 9 (IQR, 7-12.7; maximum possible score, 20), which indicates moderate lung involvement. The baseline prevalence of GGOs decreased from 100% to 2% of participants at 1 year, and that of consolidations decreased from 71% to 0% at 6 months. Fibrotic-like abnormalities (pleuroparenchymal bands, linear atelectasis, bronchiectasis and/or bronchiolectasis) were detected at 3 months (50% of participants), 6 months (42% of participants), and 1 year (5% of participants). Among these, pleuroparenchymal bands were the most represented finding. Fibrotic changes (reticulation and traction bronchiectasis and/or bronchiolectasis) were detected at 3-6 months (2%) and remained stable at 1 year, with no evidence of honeycombing. At 1 year, lung abnormalities due to COVID-19 pneumonia were completely resolved in 78 of 84 (93%) participants.
conclusionResidual lung abnormalities in individuals hospitalized with moderate COVID-19 pneumonia were infrequent, with no evidence of fibrosis at 1-year chest CT. © RSNA, 2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.